Pharmacological profile of oxaprozin eye drops.
The effects of eye drops containing a propionic acid derivative (oxaprozin) at 0.1% concentration on ocular inflammation produced by sodium arachidonate in the rabbit's eye were evaluated. Furthermore, the aqueous bioavailability of the drug formulation in the uninflamed and inflamed eyes was evaluated. Oxaprozin eye drops significantly reduced the signs of ocular inflammation elicited by sodium arachidonate on conjunctiva and iris. Oxaprozin treatment significantly reduced the levels of polymorphonuclear leukocytes and protein concentration in aqueous samples obtained from the eyes treated with arachidonate. Present data suggest, for the first time, that oxaprozin may be employed topically to prevent ocular reactions where the arachidonic acid cascade is activated.
Bucolo
Claudio
C
Fidia Oftal Research Laboratories, Catania, Italy. bucocla@mbox.unict.it
Maltese
Adriana
A
D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology*; D001082:Aqueous Humor / Q000378:metabolism; D019540:Area Under Curve; D001682:Biological Availability; D003231:Conjunctivitis / Q000188:drug therapy; D008297:Male; D009504:Neutrophils / Q000187:drug effects / Q000502:physiology; D000077431:Oxaprozin; D011422:Propionates / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use; D011817:Rabbits
D000894:Anti-Inflammatory Agents, Non-Steroidal; D011422:Propionates; D000077431:Oxaprozin